Description: IFRS 17 is transforming insurance financial reporting around the world, and Latin American markets are at different stages of adoption and implementation. This webinar will provide an overview of the IFRS 17 standard and explore its practical implications for insurers in Latin America, with a particular focus on current practice and industry experience. This webinar is for actuaries, actuarial teams, and other supporting roles working with IFRI reporting requirements and IFRS 17 reporting standards applicable to insurance products. The discussion will be of interest to actuaries and other professionals working in or with insurance companies, especially in Latin America and other Spanish speaking markets, including those in life, general insurance (P&C), health, and reinsurance. The content is suitable for a wide range of experience levels, from early career to senior practitioners with responsibility for financial reporting, valuation, or risk management under IFRS 17. If you are IFRS implementer regardless of the stage of implementation or an IFRS practitioner, this session is for you! Come learn about the resources from the SOA that can support your work, including an IFRI Certificate that offers a recognition of your skills and knowledge of this area. There will be an opportunity to ask questions in the Q & A part of the session. The webinar will be conducted in English with an option to submit questions in English or Spanish. Learning outcomes By the end of the webinar, participants will be able to: Describe the state of IFRS 17 implementation readiness across Latin America. Identify next steps and SOA professional resources to support ongoing IFRS 17 and IFRI reporting work.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This report explores AI bias in insurance and health data, highlighting the ethical role of actuaries and offering cross-disciplinary guidance for fairer decision-making systems.

Description: Article on the history of the Long Term Care Discussion Group, a Washington DC-based venue for discussing long-term care and related issues for over 20 years.

Description: Update on NAIC Activities

Description: Recognizing the benefit for actuarial discussions about how COVID-19 will affect our work, the Smaller Insurance Company Section of the Society of Actuaries hosted “COVID-19: What a Smaller Insurance Company Actuary Needs to Know Virtual Town Hall” on April 17, 2020. The following delves into these presentations and discussions.

Description: A discussion of the many developments affecting taxation of life insurance companies and products.

Description: The article discusses the role played by the "Blue Books" issued by the Congress's Joint Committee on Taxation and the authority accorded them by a recent U.S. Supreme Court decision.

Description: The article reviews the creation and interpretation of federal tax law, with specific application to the life insurance industry

Description: This is Part 2 of 2 on changes affecting Medigap insurers. It focuses on marketing and regulatory differences between Medigap and Medicare Advantage that affect the competitiveness of Medigap plans.